The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 05, 2017

Filed:

Jul. 30, 2014
Applicants:

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);

Board of Trustees of the University of Illinois, Urbana, IL (US);

Inventors:

Eduardo M. Sotomayor, Tampa, FL (US);

Joel A. Bergman, Chicago, IL (US);

Alan P. Kozikowski, Chicago, IL (US);

Alejandro V. Villagra, Tampa, FL (US);

Karrune V. Woan, Gainesville, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 275/34 (2006.01); C07D 213/75 (2006.01); C07D 231/56 (2006.01); C07D 233/26 (2006.01); C07D 233/74 (2006.01); C07D 233/78 (2006.01); C07D 239/42 (2006.01); C07D 261/14 (2006.01); C07D 209/14 (2006.01); C07D 295/13 (2006.01); C07C 275/28 (2006.01); C07C 275/40 (2006.01); A61K 31/17 (2006.01); A61K 31/185 (2006.01); A61K 31/4045 (2006.01); A61K 31/416 (2006.01); A61K 31/42 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); A61K 31/505 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07C 275/34 (2013.01); A61K 31/17 (2013.01); A61K 31/185 (2013.01); A61K 31/4045 (2013.01); A61K 31/416 (2013.01); A61K 31/42 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/505 (2013.01); A61K 45/06 (2013.01); C07C 275/28 (2013.01); C07C 275/40 (2013.01); C07D 209/14 (2013.01); C07D 213/75 (2013.01); C07D 231/56 (2013.01); C07D 233/26 (2013.01); C07D 233/74 (2013.01); C07D 233/78 (2013.01); C07D 239/42 (2013.01); C07D 261/14 (2013.01); C07D 295/13 (2013.01);
Abstract

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Specifically, the disclosed subject matter relates to compounds having activity as selective HDAC6 inhibitors, methods of making and using the compounds, and compositions comprising the compounds. In still further aspects, the disclosed subject matter relates to methods for treating oncological disorders in a patient. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.


Find Patent Forward Citations

Loading…